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A new TAO kinase inhibitor reduces tau
phosphorylation at sites associated with
neurodegeneration in human tauopathies
Caterina Giacomini1, Chuay-Yeng Koo1, Natalia Yankova2, Ignatius A. Tavares1, Selina Wray3, Wendy Noble2,
Diane P. Hanger2 and Jonathan D. H. Morris1*
Abstract
In Alzheimer’s disease (AD) and related tauopathies, the microtubule-associated protein tau is highly phosphorylated
and aggregates to form neurofibrillary tangles that are characteristic of these neurodegenerative diseases. Our previous
work has demonstrated that the thousand-and-one amino acid kinases (TAOKs) 1 and 2 phosphorylate tau on more
than 40 residues in vitro. Here we show that TAOKs are phosphorylated and active in AD brain sections displaying
mild (Braak stage II), intermediate (Braak stage IV) and advanced (Braak stage VI) tau pathology and that active
TAOKs co-localise with both pre-tangle and tangle structures. TAOK activity is also enriched in pathological tau
containing sarkosyl-insoluble extracts prepared from AD brain. Two new phosphorylated tau residues (T123 and T427)
were identified in AD brain, which appear to be targeted specifically by TAOKs. A new small molecule TAOK
inhibitor (Compound 43) reduced tau phosphorylation on T123 and T427 and also on additional pathological sites
(S262/S356 and S202/T205/S208) in vitro and in cell models. The TAOK inhibitor also decreased tau phosphorylation in
differentiated primary cortical neurons without affecting markers of synapse and neuron health. Notably, TAOK activity
also co-localised with tangles in post-mortem frontotemporal lobar degeneration (FTLD) brain tissue. Furthermore, the
TAOK inhibitor decreased tau phosphorylation in induced pluripotent stem cell derived neurons from FTLD patients, as
well as cortical neurons from a transgenic mouse model of tauopathy (Tau35 mice). Our results demonstrate that
abnormal TAOK activity is present at pre-tangles and tangles in tauopathies and that TAOK inhibition effectively
decreases tau phosphorylation on pathological sites. Thus, TAOKs may represent a novel target to reduce or prevent
tau-associated neurodegeneration in tauopathies.
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Introduction
Pathological aggregation of highly phosphorylated tau and
the formation of neurofibrillary tangles (NFTs) in the brain
provide one of the main characteristic pathological features
of a subgroup of neurodegenerative disorders termed tauo-
pathies. Alzheimer’s disease (AD) is the most prevalent
tauopathy but similar tangle-like features are also displayed
in frontotemporal lobar degeneration (FTLD), Pick’s dis-
ease, progressive supranuclear palsy and corticobasal de-
generation [17, 19]. The presence of extracellular plaques
of beta-amyloid (Aβ) provides an additional hallmark for
AD. However, the emergence of tau pathology appears to
correlate more closely than plaques with the progression of
cognitive impairment in AD [26].
Human tau is encoded by the MAPT gene located on
chromosome 17 and alternative splicing of exons 2, 3
and 10 produces six tau isoforms containing up to two
inserts at the N terminus (0 N, 1 N or 2 N) and three or
four repeated sequences (3R or 4R) at the C terminus of
the protein [8, 36]. Tau is expressed predominantly in
neurons and is a major microtubule-associated protein
(MAP) involved in the regulation of microtubule dynam-
ics and organisation [13, 58]. Tau splicing is develop-
mentally regulated and only the shortest 0N3R tau
isoform is expressed in the foetal brain, whereas all six
tau isoforms are present in the adult central nervous
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system (CNS) [8, 36]. In AD and related tauopathies, ab-
errant tau phosphorylation results in its dissociation
from microtubules and the aggregation of tau in the
cytosol to form NFTs [23, 34]. The relative importance
of individual or combinations of phosphorylated tau
residues remains to be determined. Phosphorylation
of the KXGS repeated motifs (notably S262 and S356)
located in the C-terminal microtubule binding domain
are involved in regulating tau microtubule-binding, as
are additional phosphorylation sites flanking this re-
gion [1–3, 22].
A number of protein kinases have been shown to tar-
get tau, at least in vitro, including microtubule-affinity
regulating kinase (MARK), glycogen synthase kinase 3
(GSK-3), cyclin-dependent kinase 5 (CDK5), Fyn and
also extracellular signal regulated kinase 2 (ERK2), c-Jun
N-terminal kinase (JNK) and p38 mitogen-activated pro-
tein kinases (MAPKs) [3, 24, 33, 40, 48, 61]. An import-
ant challenge for dementia is to identify kinases that are
catalytically active, associated with tangles, and are
therefore likely to contribute directly to the development
of tau pathology [20]. Previously, we have reported that
the thousand-and-one amino acid kinases (TAOKs, also
referred to as prostate-derived sterile 20-like kinases
(PSKs)) phosphorylate tau on multiple disease-associated
sites and that these kinases are activated in AD brain
[55]. TAOKs belong to the sterile 20 group of mamma-
lian protein kinases, with family members including
TAOKs 1–3 [9, 25, 44, 69]. TAOK1 and TAOK2 can
regulate MAPKs and stimulate JNK and p38 MAPK sig-
nalling pathways [9, 25, 44, 68, 69]. TAOK1 and TAOK2
also induce apoptotic changes via activation of JNK,
MAPK and caspases; however, a key feature of TAOKs is
their ability to regulate microtubule dynamics and or-
ganisation [38, 43, 56, 68]. TAOK1 induces microtubule
instability through its direct activation of MARK and
phosphorylation of MAPs, including tau, which dissoci-
ate from microtubules, resulting in their disassembly
[55–57]. TAOK2 binds to microtubules directly through
its C terminus (amino acids 745–1235), leading to stabil-
isation of perinuclear microtubules, which contain in-
creased acetylated α–tubulin and are resistant to
nocodazole-induced depolymerisation [43].
Although very little is known about the relationship of
TAOKs to neurodegenerative diseases, the TAOK2 gene
is located on chromosome 16p11.2, a region that carries
significant susceptibility for autism spectrum disorders
and schizophrenia [41, 62]. In the developing mouse
brain, TAOK2 is required for basal dendritic develop-
ment and callosal axon projection in cortical neurons,
where it acts downstream of the neuropilin-1 receptor
for semaphorin 3A, to regulate dendrite arborisation and
axon elongation through JNK [10]. Phosphorylation of
TAOK1 (pT440) and TAOK2 (pT475) by mammalian
sterile 20-like kinase 3 (MST3) results in myosin Va
binding and subsequent localisation of these kinases to
dendrites, where they regulate spine and synapse devel-
opment [59]. TAOK2 also mediates post-synaptic density
protein 95 (PSD95) stability and dendritic spine maturation
via phosphorylation and relocation of the cytoskeletal
GTPase septin 7 [65]. A recent study has also identified
three missense mutations in TAOK2 in autism spectrum
disorder subjects and shown that the expression of mu-
tated forms of TAOK2 or increased expression of wild type
TAOK2 impairs dendritic spine development in primary
neurons [49]. These studies demonstrate important func-
tions for TAOK2 during early brain development; however,
the potential roles for TAOKs in the adult brain and in the
aberrant phosphorylation of tau in tauopathies have not
yet been explored.
In this study, we have investigated the effects of tau
phosphorylation resulting from TAOK activity and in-
hibition using a new small molecule inhibitor. We found
that TAOK activity was present in pre-tangles and tan-
gles in AD and FTLD brain, whereas it was only weakly
detectable in control human brain. TAOKs phosphory-
lated tau on pathological sites in human cell lines in
addition to murine and human neurons, and this was re-
duced by the TAOK inhibitor. Our findings implicate
the TAOKs as important contributors to the develop-
ment of tau pathology in AD and FTLD.
Materials and methods
Plasmids, antibodies and reagents
Plasmids pRK5-TAOK1, pRK5-TAOK2, pRK5-TAOK2
(K57A) and pRK5-TAOK2 (amino acids 1–349) were gen-
erated as described previously [44, 69] and subcloned into
pCAGGS-IRES-EGFP or pCAGGS-IRES-Tomato vectors
(gift from Dr. L. Gasparini, Italian Institute of Technology,
Genoa, Italy). PLenti-lox3.7 vectors expressing TAOK2-
shRNA or non-targeting-shRNA and enhanced green
fluorescent protein (EGFP) using an alternative promoter
were a gift from Dr. S. Ultanir (Crick Institute, London,
UK). Tau-pT123, tau-pT427 and TAOK-pS181 affinity-
purified rabbit antibodies and peptides were produced by
Eurogentec. Mouse tau-pS262/S356 antibody (12E8) was
a gift from Dr. P. Seubert (Prothena, USA). Commercially
available mouse monoclonal antibodies were obtained to
detect TAOK1 (BD), tau-pS202/T205/S208 (AT8, Thermo
Fisher Scientific), total tau (Tau5, Thermo Fisher Scien-
tific), synaptophysin (SP15, Enzo), Myc (9E10, Sigma-
Aldrich) and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Merck Millipore). Rabbit antibodies were ob-
tained to recognise TAOK1 and TAOK2 (Proteintech),
BIII Tubulin (Sigma-Aldrich), total tau (Dako), synap-
sin 1 (Merck Millipore) and active cleaved caspase III
(R&D Systems). GST-TAOK1 (amino acids 1–314) and
GST-TAOK2 (amino acids1–314) were obtained from
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SignalChem. Reagents and chemicals were purchased
from Sigma-Aldrich and cell culture reagents were ob-
tained from Thermo Fisher Scientific, unless otherwise
stated. Compound 43 was made by Evotec as described
previously [29].
Immunostaining of human brain tissue
Clinically and pathologically confirmed post-mortem hu-
man AD, FTLD and control brains (Additional file 1:
Table S1) were obtained from the MRC London Neurode-
generative Disease Brain Bank (King’s College London).
Tissue sections (7 μm) were cut from formalin-fixed
paraffin-embedded blocks of human brain. Sections were
deparaffinised and endogenous peroxidase activity inhib-
ited by incubating samples in 3% (v/v) hydrogen peroxide
(30 min) followed by antigen retrieval using enhanced
microwaving in 10 mM sodium citrate buffer (20 min)
(pH 6.0). Sections were blocked for 1 h in 10% (v/v)
goat serum before incubation overnight with TAOK-
pS181, tau-pT123 or tau-pT427 antibodies (4 °C). Sec-
tions were incubated with goat anti-rabbit-biotinylated
secondary antibodies (45 min, Dako) and developed
using the VECTASTAIN Elite ABC kit (Vector Laborator-
ies) and 0.5 mg/ml 3, 3′-diaminobenzidine chromogen
(Vector Laboratories). All sections were counterstained
with hematoxylin. For double immunofluorescence la-
belling, sections were pre-treated as described above,
and incubated overnight with phospho-tau antibodies
(4 °C) followed by secondary goat anti-rabbit 568 or
goat anti-mouse 488 Alexa Fluor antibodies (Thermo
Fisher Scientific). Autofluorescence was quenched by
Sudan black (0.1% Sudan black in 70% ethanol) and
images were acquired using a CSU-X1 inverted spinning-
disk confocal microscope (Nikon) equipped with EM-
CCD camera (Andor iXon3) and a 60×/1.40 NA oil
objective (Nikon).
Extraction of sarkosyl-insoluble tau
Sarkosyl extraction of tau from brain tissue was per-
formed as described previously [30]. Briefly, brain tissues
were homogenised in 50 mM Tris buffered saline (TBS,
pH 7.4) containing 2 mM EGTA, 1 mM Na3VO4,
10 mM NaF and 1 mM phenylmethylsulfonyl fluoride.
Samples were centrifuged at 20,000 g for 20 min (4 °C)
and sarkosyl (10% v/v) was added to the resultant super-
natant to give a final concentration of 1% (v/v). Samples
were mixed for 30 min at ambient temperature, then
centrifuged at 100,000 g for 1 h at ambient temperature.
The supernatant was collected and the pellet washed
twice with 1% (v/v) sarkosyl before solubilisation in 2×
sodium dodecyl sulphate (SDS) sample buffer (National
Diagnostics). The three fractions produced comprised (i)
low speed supernatant, (ii) sarkosyl-soluble tau, and (iii)
sarkosyl-insoluble tau. Proteins in the samples were
resolved by SDS gel electrophoresis (SDS-PAGE) and
processed for immunoblotting.
In vitro kinase assays
3 μg human recombinant tau (2N4R isoform, Sigma-
Aldrich) and 30 ng purified glutathione S-transferase
(GST)-TAOK1 (1–314) or GST-TAOK2 (1–314) were
incubated in kinase buffer (20 mM MgCl2, 2 mM
MnCl2, 3 mM ATP and 30 mM Tris, pH 7.4) for 6 h at
30 °C. Reactions were terminated in 5× Laemmli gel
sample buffer (10% SDS, 50% glycerol, 0.05% bromophe-
nol blue, 350 mM dithiothreitol and 1 M Tris, pH 6.8).
Samples were resolved by SDS-PAGE and protein phos-
phorylation was analysed on immunoblots probed with
appropriate antibodies.
Culture of HEK293T cells and primary cortical neurons
Human embryonic kidney (HEK) 293 T cells were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM,
Sigma-Aldrich), supplemented with 10% (v/v) foetal calf
serum (FCS, Thermo Fisher Scientific) and antibiotics, at
37 °C in an atmosphere of 5% CO2. Cells were trans-
fected using Lipofectamine 2000 (Thermo Fisher Scien-
tific) according to the manufacturer’s instructions.
Cultured HEK293T cells were incubated with TAOK in-
hibitor compound 43 (Cp 43), or equivalent concentra-
tions of vehicle dimethyl sulfoxide (DMSO and to a
maximum of 0.3%), for 24 h. Treated cells were col-
lected, lysed and analysed on western blots. Rat primary
cortical neurons were prepared from embryonic (E) day
18.5 brains as described previously [16] and neurons
were seeded onto poly-L-lysine–coated coverslips or 6
well plates at 3–8 × 104 cells per coverslip (18 mm) or at
5 × 105 cells per well. Neurons in neurobasal medium
containing B-27, GlutaMAX and antibiotics (Thermo
Fisher Scientific) were cultured at 37 °C, in an atmos-
phere of 5% CO2. Primary cortical neurons were pre-
pared from Tau35 transgenic mice [4] and cultured as
described above. Neurons were treated with Cp 43 or
vehicle for the indicated times and concentrations, add-
ing fresh inhibitor daily for longer time points. Cells
were either lysed for analysis on western blots or stained
for immunofluorescence analysis. Neurons transfected
with Lipofectamine 2000 were fixed and stained for im-
munofluorescence analysis. All methods were carried
out in accordance with the UK Animals (Scientific Pro-
cedures) Act 1986.
Culture of induced pluripotent stem cell-derived neurons
Induced pluripotent stem cells (iPSCs) from control and
FTLD patients carrying the MAPT 10 + 16 mutation
were prepared as described previously [53]. IPSCs were
differentiated into cortical neurons using dual SMAD in-
hibition followed by in vitro neurogenesis, as described
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previously [52, 53]. After culture for 28–30 days in vitro
(DIV), when a substantial amount of neurogenesis had
occurred, cells were plated onto poly-ornithine and lam-
inin coated plates (Sigma-Aldrich) or on eight-well
chamber slides for immunofluorescence (Ibidi) and fed
every two days with neuronal maintenance media (N-2
medium and B-27 medium, ratio 1:1). N-2 medium
consists of DMEM/F-12 GlutaMAX containing 1 x N-2,
5 μg/ml insulin, 1 mM L-glutamine, 100 μM non-essential
amino acids, 100 units M2-mercaptoethanol, 50 U/ml
penicillin and 50 mg/ml streptomycin. B-27 medium
consists of Neurobasal medium containing 1 x B-27,
20 mM L-glutamine, 50 U/ml penicillin and 50 mg/ml
streptomycin (Thermo Fisher Scientific). Neurons were
treated with Cp 43 or vehicle, and cultures were either
lysed for immunoblotting or stained for immunofluores-
cence analysis at 60 DIV.
Immunofluorescence
Primary cortical neurons were fixed with 4% (w/v) para-
formaldehyde (PFA) in phosphate-buffered saline (PBS,
pH 7.4) for 15 min, permeabilised with 0.2% (w/v) Triton
X-100 in PBS for 5 min, and blocked with 10% (v/v) goat
serum and 0.25% (w/v) Triton X-100 in PBS for 30 min.
Neurons were incubated sequentially overnight at 4 °C
with appropriate primary antibodies followed by Alexa
Fluor 488-, 568- or 647-conjugated secondary anti-
bodies (2 h). Coverslips were mounted using Prolong
Gold (Thermo Fisher Scientific) containing 4′, 6′-diami-
dino-2-phenylindole (DAPI) to label nuclei. To quantify
tau phosphorylation on threonine 427 (T427) in neurons
transfected with TAOK2 and treated with Cp 43 or ve-
hicle, z-stack confocal images were acquired using fixed
laser and scanning settings. Mean immunofluorescence
intensity was measured using ImageJ software [50]. Re-
sults are expressed as the amount of tau-pT427/tau5 (total
tau) immunofluorescence intensity.
Cytotoxicity assays
Rat primary neurons were treated with Cp 43 (6 h) and
cytotoxicity assessed by measuring LDH release into the
culture medium using a Cytotox 96 assay kit (Promega,
Madison, WI, USA), according to the manufacturer’s in-
structions. Optical density was measured at 492 nm and
LDH release from neuronal cultures was expressed as a per-
centage of total LDH in each sample. Cytotoxicity was also
assessed by quantifying through immunofluorescence stain-
ing the number of active caspase 3-positive cells following
treatment with Cp 43 (72 h). Quantification was carried out
on blind-coded sample images using ImageJ software.
Western blotting
HEK293T cells, primary and iPSC derived neurons were
lysed in RIPA buffer (1% NP-40, 0.1% SDS, 150 mM
NaCl and 50 mM Tris pH 7.5) supplemented with prote-
ase and phosphatase inhibitors (Sigma-Aldrich). Lysed
cells were sonicated for 5 min and clarified by centrifu-
gation at 10,000 g for 10 min at ambient temperature.
Protein concentrations were determined using a bicinch-
oninic acid assay (Thermo Fisher Scientific). Equal
amounts of protein (15–30 μg) in 5× Laemmli sample
buffer were resolved by SDS-PAGE and transferred to 0.
2 μm nitrocellulose membranes (GE Healthcare). Mem-
branes were blocked in 5% (w/v) skimmed milk in buffer
(150 mM NaCl, 0.1% Tween 20 and 10 mM Tris, pH 7.5),
incubated with appropriate primary antibodies overnight at
4 °C, followed by horse radish peroxidase (HRP)-conjugated
secondary antibodies (Dako) for 1 h at ambient temperature.
Protein bands were visualised using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Fisher Scientific) and
Hyperfilm ECL (GE Healthcare) and densitometric analysis
was carried out using ImageJ software.
Statistical analysis
Statistical analysis of data was performed using Student’s
t-test for two groups or ANOVA followed by the
Holm-Sidak post hoc test in case of multiple compar-
isons (Sigma Plot 13.0 Software). Differences between
groups were considered statistically significant when
p < 0.05. Results are reported as mean values ± SEM,
except when specified otherwise.
Results
Active TAOK-pS181 associates with tau pathology in AD
and FTLD brain
Previously, we have used a phospho-antibody (TAOK-
pS181) to detect forms of TAOK1 and TAOK2 that are
catalytically active and phosphorylated on serine residue
181 (S181) as part of their conformational activation
[63, 66, 68]. To investigate the contribution of TAOKs to
the development of tau pathology and disease progression
in AD, serial sections were prepared from the entorhinal
cortex of AD brain displaying mild (Braak stage II, n = 3),
moderate (Braak stage IV, n = 3) or severe (Braak
stage VI, n = 4) pathology alongside control brain (n = 4)
(Additional file 1: Table S1) [5]. Sections (× 12 per
brain sample) were immunostained with the TAOK-
pS181 antibody, and strong positive immunoreactivity
was observed in tangles and pre-tangle structures in
all sections from AD brains with mild, moderate or
severe Braak stages (Fig. 1a, Braak stages II, IV, VI).
In contrast, no tangle-like structures were apparent
with TAOK-pS181 staining in control brain (Fig. 1a).
The accumulation of highly phosphorylated tau aggre-
gates at tangles not only provides a key feature for
AD but is also characteristic for a number of related
tauopathies, including frontotemporal lobar degener-
ation with tau-immunoreactive inclusions (FTLD-tau)
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[17]. Consequently, entorhinal cortex sections (× 12 per
brain sample) from two individuals with FTLD-tau
were immunostained with the TAOK-pS181 antibody
and positive immunoreactivity was detected in tangle-
like structures in all sections (Fig. 1a, Additional file 1:
Table S1). These results imply that TAOK activity may
also contribute to tau pathology and tangle formation
in additional tauopathies such as FTLD-tau.
The association between TAOK expression and activ-
ity and tau pathology was investigated further by prepar-
ing extracts from the entorhinal cortex of two Braak
stage VI AD and two control brains. Low speed superna-
tants (LSS), sarkosyl-soluble (SS) and sarkosyl-insoluble
(SI, insoluble tau) brain fractions were analysed on west-
ern blots probed with antibodies recognising active
TAOKs, TAOK1, TAOK2 or GAPDH (Fig. 1b). TAOK1
(~ 110 kDa) and TAOK2 (~ 175 kDa) displayed apparent
molecular weights that were similar to those reported
previously for TAOK1 and TAOK2 [25, 44] and their ex-
pression levels in AD and control samples were compar-
able in the SI fraction (Fig. 1b). Phosphorylated and
active TAOK1 and TAOK2 are recognised by the TAOK-
pS181 antibody [63] and these phosphorylated proteins
are increased in SI fractions prepared from AD brain com-
pared to control brain (Fig. 1b). Additional immunoblot-
ting with phospho-tau and total tau antibodies showed
that tau-pS202/S205/S208 (AT8) and tau-pS262/S356
(12E8) were enriched in the sarkosyl-insoluble fraction of
AD brain, in which active TAOK-pS181 was also increased
(Fig. 1b). Taken together, these results demonstrate that
TAOK activity is increased in AD brain compared to con-
trols and this kinase activity co-localises with mild, moder-
ate and severe tau pathology during disease progression.
Furthermore, while both TAOK1 and TAOK2 were appar-
ent in the SI fraction of both control and AD brain, active
TAOKs appeared to be enriched in SI fraction containing
pathological aggregated tau species in AD brain.
Compound 43 inhibits tau phosphorylation by TAOK2
in vitro and in cells
We have identified a small molecule inhibitor of TAOKs,
termed compound 43 (Cp 43) [29]. Cp 43 has an IC50 of
11–15 nM, is ATP-competitive and targets TAOKs select-
ively [29]. In vitro kinase assays were used to determine
whether Cp 43 could inhibit the phosphorylation of
tau by TAOK2. Purified recombinant TAOK2 (amino
acids 1–314) containing the catalytic domain, was incu-
bated with recombinant human tau (htau, 2N4R isoform)
in vitro in the presence of increasing concentrations of Cp
43 (5–60 μM) and samples were analysed by immunoblot-
ting with 12E8 and AT8 phospho-tau antibodies. Cp 43
inhibited phosphorylation of tau by TAOK2 in a dose-
dependent manner (Fig. 2a).
To investigate the effects of TAOK2 on tau phosphoryl-
ation in cells, HEK293T cells were transfected with con-
structs to express Myc-TAOK2 (1–349) or kinase-defective
Myc-TAOK2 (1–349, K57A) and htau (2N4R), and cell
lysates were probed with AT8 antibody. Figure 2b shows
that exogenous TAOK2, but not kinase-defective TAOK2
Fig. 1 TAOK-pS181 associated with tau pathology in AD and FTLD-tau
brain. a Formalin-fixed sections from the entorhinal cortex of AD (Braak
stages II, IV and VI), FTLD-tau or control brains were immunostained with
antibody to detect phosphorylated and active TAOKs (TAOK-pS181).
Strong positive antibody immunoreactivity was observed on NFTs in
AD brain sections from early and late disease stages and in FTLD brain
sections (arrows indicate magnified NFTs). b AD (Braak VI) or control
(CTR) entorhinal cortex brain samples were extracted with sarkosyl and
low speed supernatants (LSS) or sarkosyl-soluble (SS) or sarkosyl-insoluble
(SI, insoluble tau) fractions immunoblotted with antibodies to detect
TAOK1, TAOK2, TAOK-pS181 and GAPDH or tau-pS262/S356 (12E8),
tau-pS202/T205/S208 (AT8), total tau and GAPDH. Representative images
and immunoblots are shown. Scale bar = 20 μm
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(K57A), enhanced tau phosphorylation on the AT8 epitope.
HEK293T cells expressing TAOK2 and htau were also
incubated with increasing concentrations of Cp 43 (5–
30 μM) to determine whether this small molecule was
able to inhibit tau phosphorylation by TAOK2 in cells.
Figure 2c-d shows that Cp 43 (30 μM) significantly
reduced TAOK2-mediated tau phosphorylation on the
AT8 epitope. Taken together, these results demon-
strate that Cp 43 can inhibit tau phosphorylation by
TAOK2 in vitro and in cells.
TAOKs are expressed and active in differentiating cortical
neurons
Previous studies have demonstrated that TAOK2 is
expressed in the brains of developing mouse embryos
[10, 59]. Therefore, we investigated TAOK expression
and activity during differentiation of rat primary cortical
neurons. Lysates prepared from cortical neurons at 3, 7,
10, and 14 days in vitro (DIV) were immunoblotted with
antibodies to detect TAOK-pS181, TAOK2, or TAOK1.
The activity and expression of TAOKs increased be-
tween 3 and 14 DIV relative to βIII-tubulin, in parallel
with increases in total and phosphorylated tau recog-
nised by AT8 and 12E8 (Fig. 3a).
To further investigate the activity of TAOKs during
differentiation, cortical neurons at 5 DIV were trans-
fected with a bicistronic vector expressing EGFP as a re-
porter, together with Myc-TAOK1, Myc-TAOK2, the
catalytic domain of TAOK2 (amino acids 1–349) or full-
length kinase-defective TAOK2 (K57A). Neurons were
Fig. 2 Cp 43 reduced tau phosphorylation by TAOK2. a In vitro kinase assays were carried out using GST-TAOK2 (1–314) and/or recombinant htau
(2N4R) in the presence or absence of Cp 43 as indicated. Samples were immunoblotted with antibodies to detect tau-pS262/S356 (12E8), tau-pS202/
T205/S208 (AT8) or total tau. b HEK293T cells were co-transfected with empty vector (EV), kinase-deficient TAOK2 (1–349, K57A) or TAOK2 (1–349) and
htau (2N4R) as indicated, and cell lysates immunoblotted with antibodies to detect, TAOK-pS181, tau-pS202/T205/S208 (AT8), total tau, Myc or GAPDH.
c HEK293T cells were co-transfected with empty vector (EV) or TAOK2 (1–349) and htau (2N4R), and treated with or without Cp 43 as indicated. After
24 h, cell lysates were immunoblotted with antibodies to detect tau-pS202/T205/S208 (AT8), total tau, Myc or GAPDH. d Quantitative analysis of the
relative levels of tau-pS202/T205/S208 versus total tau in transfected HEK293T cells is shown. The data are normalised to total tau and the bars
represent the average ratio ± SEM (n = 4); **p < 0.01, one-way ANOVA followed by multiple comparison with the Holm-Sidak method
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fixed 48 h after transfection and immunostained with
antibodies to detect either Myc (TAOKs) or active
TAOK-pS181. Exogenous expression of both TAOK1
and TAOK2 was confirmed by detection of the Myc tag
in transfected neurons, however, only TAOK2 was ac-
tive, as detected by the TAOK-pS181 antibody (Fig. 3b).
Full-length TAOK2 (both wild-type and K57A) localised
to the perinuclear microtubule cage in differentiating
neurons (Fig. 3b), as described previously [43]. In
contrast, the catalytic domain of TAOK2 (1–349),
which lacks the microtubule binding region (amino
acids 745–1235) [43], was distributed throughout the
cytoplasm and neurites (Fig. 3b). Expression of full-
length and kinase-defective TAOK2 (K57A) in cortical
neurons provided a negative control, which was de-
tected by the Myc antibody but not the TAOK-pS181
antibody (Fig. 3b). Exogenous TAOK2 was therefore
expressed and catalytically active in transfected cor-
tical neurons.
TAOK inhibition reduces tau phosphorylation in rat
primary cortical neurons
To evaluate the effects of TAOK inhibition on tau
phosphorylation in primary rat cortical neurons, cultures
at 7 and 17 DIV were treated with Cp 43 (5, 10, 30 μM)
for 72 h prior to analysis on western blots. Cp 43 (30 μM)
caused significant reductions in tau phosphorylation
at the 12E8 and AT8 epitopes, relative to total tau, in
neurons cultured for both 7 and 17 DIV (Fig. 4a-d).
TAOK inhibition did not increase the number of ac-
tive caspase-3 positive 7 or 17 DIV neurons treated
with Cp 43 (30 μM) for 72 h or affect the expression
of the pre-synaptic proteins synapsin 1 and synapto-
physin in 17 DIV neurons (Additional file 2: Figure
S1 A-C). Cp 43 was able to reduce tau phosphoryl-
ation significantly after 6 h of incubation even at a
lower concentration of 10 μM (Additional file 2:
Figure S1 D-E). The release of lactate dehydrogenase
(LDH) into the culture medium was also used to as-
sess cytotoxicity. 7 and 17 DIV neurons were incu-
bated with increasing concentrations of Cp 43 (6 h)
and the release of LDH into the culture medium de-
termined. Cp 43 did not affect LDH levels in the
media or appear to be cytotoxic under these condi-
tions (Additional file 2: Figure S1F). Taken together,
these results show that TAOK inhibition can reduce
tau phosphorylation in differentiating neurons without
inducing significant cytotoxicity.
Fig. 3 Primary cortical neurons expressed active TAOK-pS181. a Neurons were cultured for 3, 7, 10 or 14 DIV and lysates immunoblotted with
antibodies to detect TAOK-pS181, TAOK1, TAOK2, tau-pS202/T205/S208 (AT8), tau-pS262/S356 (12E8), total tau or BIII tubulin as indicated. b Neurons
were transfected with pCAGS-Myc-TAOK1-IRES-EGFP (TAOK1-GFP), pCAGS-Myc-TAOK2-IRES-EGFP (TAOK2-EGFP), pCAGS-Myc-TAOK2–1-349-IRES-EGFP
(TAOK2–1-349-EGFP), pCAGS-Myc-TAOK2-K57A-IRES-EGFP (TAOK2 K57A-EGFP) or pCAGS-IRES-EGFP (EGFP) plasmids, as indicated. 7 DIV transfected
neurons were fixed and immunostained with antibodies to detect active TAOK-pS181 (red) and Myc (magenta). Nuclei were counterstained with DAPI
(blue) and representative maximal projection of confocal z-stack images is shown. Scale bar = 10 μm
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Two new tau residues (T123 and T427) are
phosphorylated by TAOK2 and associate with tangles
in AD and FTLD-tau brain
Mass spectrometric analysis has identified 49 tau resi-
dues that are phosphorylated by TAOK1 and TAOK2
in vitro, including several sites that are phosphorylated ab-
errantly in AD brain [55]. The phosphorylation of
two of these AD-tau residues, T123 and T427, has
not yet been attributed to the activity of any alterna-
tive kinases and may therefore be specific to TAOKs
(https://bit.ly/1SpzgoL). Therefore, we generated two
new phospho-tau antibodies to detect tau-pT123 and
tau-pT427, and these were used to monitor TAOK
activity in human brain and cell experimental models.
In vitro kinase assays were carried out using recom-
binant htau (2N4R) and purified TAOK1 (1–314) or
TAOK2 (1–314), and phosphorylation of tau on both
sites was detected on western blots using antibodies tau-
pT123, tau-pT427 and 12E8 (Fig. 5a). Entorhinal cortex
sections (× 12 per brain sample) from brains presenting
mild (Braak stage II, n = 3), moderate (Braak stage IV,
n = 3) or severe (Braak stage VI, n = 4) AD pathology, or
from FTLD-tau brains (n = 2) or control brains (n = 4),
were immunostained with the tau-pT123 and tau-pT427
antibodies. Tangle-like structures were labelled with
both the tau-pT123 and tau-pT427 antibodies in all
AD (Braak stages II, IV and VI) and FTLD-tau sec-
tions (Fig. 5b-c). Immunoreactivity was also detected
in some nuclei in AD and FTLD-tau brain and to a
lesser extent in controls (Fig. 5b-c).
Epitope specificity for the tau-pT123, tau-pT427 and
TAOK-pS181 antibodies was confirmed by pre-treating
these reagents with their appropriate phospho-peptides,
which blocked antibody recognition of their target epitopes
in immunostained AD sections and in immunoblotted in
vitro kinase assays (Additional file 3: Figure S2A-B). Tau-
pT123 and tau-pT427 antibody labelling co-localised
with 12E8 and AT8 in AD sections, confirming label-
ling of tangles by both of the new phospho-dependent
tau antibodies (Fig. 5d). Extracts from the entorhinal
cortex of AD (Braak VI; n = 2) and control brains (n = 2)
showed that tau-pT123 and tau-pT427 were enriched
in the sarkosyl insoluble (SI) fractions extracted from
AD but not control brains (Fig. 5e). The results pre-
sented here confirm that both of these tau residues are
targeted by TAOKs and show that tau is phosphorylated
Fig. 4 Cp 43 reduced tau phosphorylation in primary cortical neurons. a, c Lysates were prepared from 7 DIV (a) or 17 DIV(c) neurons treated
with or without Cp 43 for 72 h as indicated and immunoblotted with antibodies to detect tau-pS262/S356 (12E8), tau-pS202/T205/S208 (AT8),
total tau or BIII Tubulin. b, d Quantitative analysis of the effects of increasing Cp 43 concentration on the levels of phosphorylated tau, 12E8 and
AT8 epitopes, in 7 DIV (b) and 17 DIV neurons (d). The data are normalised to total tau and the bars represent the average ratio ± SEM (n = 7).
*p < 0.05, one-way ANOVA followed by multiple comparison with the Holm-Sidak method
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on T123 and T427 in early and late-stage AD and also in
FTLD-tau brain.
TAOK2 activity is required to phosphorylate tau on T427
in cortical neurons
Tau phosphorylation on T123 and T427 was investigated
next in rat primary cortical neurons using a bi-cistronic
IRES vector to express Myc-TAOK2 together with EGFP
to provide a reporter protein. 7 DIV transfected neurons
expressing exogenous active TAOK2 were strongly im-
munoreactive with the tau-pT427 antibody (Fig. 6a). In
contrast, untransfected neurons or transfected neurons ex-
pressing kinase-defective TAOK2 (K57A) or EGFP alone
were not recognised by the tau-pT427 antibody (Fig. 6a).
Fig. 5 Tau-pT123 and tau-pT427 are targeted by TAOKs and are associated with tangles in AD and FTLD-tau brain. a In vitro kinase assays were
carried out using GST-TAOK1 (1–314), GST-TAOK2 (1–314) and/or htau (2N4R) as indicated and samples immunoblotted with antibodies to detect
tau-pS262/S356 (12E8), tau-pT427, tau-pT123 or total tau. b-c Entorhinal cortices from control (CTR), AD (Braak stage II-VI) or FTLD-tau brains were
immunostained with antibodies to detect tau-pT123 (b) or tau-pT427 (c). Strong positive antibody immunoreactivity was observed for tau-pT123
and tau-pT427 at NFTs in each stage of AD and in FTLD-tau (arrows indicate magnified NFTs). d Sections from the entorhinal cortex of advanced
AD (Braak stage VI) brains were immunostained with antibodies to detect tau-pS202/T205/S208 (AT8, green) or tau-pS262/S356 (12E8, green) and
tau-pT123 or tau-pT427 (red) as indicated. Nuclei were counterstained with DAPI (blue). e AD (Braak VI) or control (CTR) hippocampal and entorhinal
cortex brain samples were extracted with sarkosyl and low speed supernatants (LSS) or sarkosyl-soluble (SS) or sarkosyl-insoluble fractions (SI, insoluble
tau) immunoblotted with antibodies to detect tau-pT123, tau-pT427 or total tau as indicated. Representative images and immunoblots are shown.
Scale bar = 20 μm
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These results demonstrate that tau is not phosphorylated
physiologically on T427 in differentiating cortical neurons.
The ability of Cp 43 to inhibit tau phosphorylation on
T123 and T427 by TAOK2 was initially tested using in
vitro kinase assays, which showed that tau phosphorylation
on these epitopes was decreased by the inhibitor com-
pound (Fig. 6b). Treatment of TAOK2 transfected cortical
neurons with Cp 43 (30 μM, 24 h) also reduced tau phos-
phorylation on T427, and tau-pT427 immunoreactivity
was decreased by 55% in neurons incubated with the in-
hibitor compared to controls (Fig. 6c-d, Cp 43 n = 70, con-
trols n = 65). In addition, co-transfection of Myc-TAOK2-
IRES-Tomato together with TAOK2-shRNAs to knock-
down expression of exogenous TAOK2 in cortical neurons
(Fig. 6e) also decreased tau-pT427 immunoreactivity
(Fig. 6f ). These results show that tau phosphorylation
on T427 was stimulated by expression of exogenous
TAOK2 in transfected neurons and that this effect
can be inhibited by treating cells with Cp 43 or by si-
lencing TAOK2 expression using shRNAs.
Although we did not observe any positive immunore-
activity in lysates from rat primary cortical neurons
immunoblotted with tau-pT123 and tau-pT427 anti-
bodies, tau-pT123 immunostaining showed a positive
signal in untransfected neurons that was restricted to
the nuclear compartment. However, this signal was not
increased following transfection and over-expression of
TAOK2 (Additional file 4: Figure S3A).
Fig. 6 Cp 43 reduced tau phosphorylation on T427 by TAOK2 in primary neurons. a IRES-EGFP and TAOK2-EGFP transfected neurons (7 DIV) were
fixed and immunostained with antibodies to detect tau-pT427 (red) and Myc (magenta). b In vitro kinase assays were carried out using GST-TAOK2
(1–314) and/or recombinant htau (2N4R) in the presence or absence of Cp 43 as indicated. Samples were immunoblotted with antibodies to detect
tau-pT123, tau-pT427, total tau or GST. c TAOK2-EGFP transfected neurons (7 DIV) were incubated with or without Cp 43 (30 μM) for 24 h as indicated
and immunostained with antibodies to detect tau-pT427 (red) or total tau (tau-5, magenta). d Quantitative analysis of tau-pT427 immunoreactivity in
TAOK2-EGFP transfected neurons incubated with or without Cp 43. Bars represent the average immunofluorescence intensity ± SEM of tau-pT427
normalised to total tau. > 65 neurons were analysed for each group (n = 4). *p < 0.05, student t-test. e-f TAOK2-IRES-Tomato and TAOK2-shRNA-EGFP
or scrambled-shRNA-EGFP were co-transfected into neurons as indicated and after 72 h cells were fixed and immunostained for TAOK2 (magenta, e)
or tau-pT427 (magenta, f). Nuclei were counterstained with DAPI (blue). Representative maximal projection of z-stack images and immunoblots are
shown. Scale bar = 10 μm
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Cp 43 decreased tau phosphorylation in murine and
human neuronal cell models of tauopathy
The positive immunoreactivity for TAOK-pS181, tau-
pT123 and tau-pT427 antibodies observed in the tangle
structures in FTLD-tau-brain suggests that TAOK activ-
ity may contribute to tau pathology in this disease.
Therefore, we decided to evaluate the effect of TAOK
inhibition on tau phosphorylation in murine and human
neuronal cell models of FTLD-tau. Previous studies have
demonstrated the presence of an N-terminally truncated
form of tau in tauopathy brains [64]. This human brain
derived tau fragment, tagged with HA to provide an epi-
tope tag, has recently been used to generate the Tau-35
mouse model, which displays key disease associated fea-
tures including enhanced tau phosphorylation and the
presence of tangle like structures in the brain [4, 54].
The activity of TAOKs and their potential contribution
to tau phosphorylation was investigated here by prepar-
ing primary cortical neurons from Tau35 transgenic
mouse embryos and incubating these cultures in the
presence or absence of Cp 43 (10 or 30 μM for 6 h). Cell
lysates were prepared at 14 DIV and western blotting
analysis detected active TAOK-pS181 and demonstrated
that treatment with Cp 43 caused significant reductions
in tau phosphorylation on the 12E8 and AT8 epitopes
(Fig. 7a-b). Tau did not appear to be phosphorylated on
T123 or T427 in these lysates prepared from Tau35
mouse neurons and this result was similar to our obser-
vations in wild-type rat primary cortical neurons.
To investigate the effects of TAOKs on tau phosphor-
ylation in human neurons, induced pluripotent stem
cells (iPSCs) from two control iPSC lines and one iPSC
line generated from an individual with the FTLD-
associated 10 + 16 MAPT mutation, were differentiated
into cortical neurons [53]. Cells were cultured for 60
DIV and neuronal morphology was analysed by expression
of MAP2, total tau, unphosphorylated tau (Tau1) and
phosphorylated tau (12E8) (Additional file 5: Figure S4).
Lysates prepared from these cells showed similar levels of
expression of TAOK1, TAOK2 and active TAOK-pS181
were detected in control and FTLD-tau samples (Fig. 7c).
Tau phosphorylation on the 12E8 epitope was comparable
in control and FTLD-tau neurons at 60 DIV (Fig. 7c).
Treatment with Cp 43 (30 μM, 6 h) caused a significant
reduction in 12E8 immunoreactivity in both control and
FTLD-tau human neurons (Fig. 7c-d). These results show
that endogenous TAOKs are active in these murine and
human neuronal models for tauopathy and that tau phos-
phorylation was decreased by Cp 43.
Discussion
An important objective for dementia research is the
identification of tau kinases that are catalytically active
at tangle structures in tauopathies and therefore likely to
contribute directly to the aberrant phosphorylation and
aggregation of tau. In this study, active TAOK-pS181
was present and detected at pre-tangles and tangles in
AD brain sections displaying mild, intermediate and ad-
vanced tau pathology (Braak stages II-VI). In contrast,
we were unable to detect significant TAOK activity in
control brain sections. Sarkosyl-insoluble extracts of AD
brain tissues (Braak stage VI) also demonstrated the pres-
ence of active TAOK-pS181 in those fractions which con-
tained aggregated and pathologically phosphorylated tau,
whereas TAOK activity and phosphorylated tau were
largely absent in extracts prepared from control brain.
These results are consistent with potential roles for
TAOKs in the development of early and late-stage tau
pathology in AD brain. The association between aberrant
phosphorylation and self-aggregation of tau in patho-
logical conditions has been well documented, however,
the precise phosphorylation events resulting in tau toxicity
are not well defined [14, 37]. KXGS motifs located within
the tau repeat domain are of special interest because tau
phosphorylation on the 12E8 epitope (S262/S356) reduces
tau-microtubule binding and contributes to the patho-
genic cascade, where tau is phosphorylated on additional
residues associated with tangle formation [22, 45]. A re-
cent study has also shown that tau phosphorylation on the
AT8 epitope (S202/T205/S208), located within the proline
rich domain, is sufficient to promote tau aggregation and
relocalisation of pathogenic tau in the dendrite compart-
ment, and these events occur during early neurodegenera-
tion in AD [11, 27]. Attenuation of tau phosphorylation
on these sites, through inhibition of appropriate tau ki-
nases, could provide a suitable strategy for the treatment
of early stage AD and related tauopathies.
Abnormal tau phosphorylation can result in aberrant
pathology via several different mechanisms, and these
appear to include changes in tau degradation pathways
and cleavage. For example, tau phosphorylated on
S262/S356 is not recognised by the C terminus of HSP70-
interacting protein-heat shock protein 90 (CHIP–HSP90)
complex and is therefore protected from proteasomal deg-
radation [12]. In addition, tau phosphorylation on S422
can prevent tau cleavage by Caspase 3 at T421 [18]. We
have demonstrated previously that TAOKs can phosphor-
ylate tau on more than 40 residues in vitro, and 29 of
these sites are modified in PHF-tau extracted from AD
brain [55]. Two of these PHF-tau residues, T123 and
T427, were investigated here because they are uncharac-
terised and could be targeted by TAOKs specifically. Im-
munohistochemical analysis of early and late stage AD
brain sections (Braak II-VI) detected tau-pT123 and tau-
pT427 at pre-tangles and tangles, where TAOK activity
also occurred. Furthermore, sarkosyl-insoluble tau from
AD brain was also phosphorylated on T123 and T427 and
this fraction also contained active TAOK-pS181.
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The presence of TAOK activity at pre-tangles and tan-
gles in early stage AD brain correlates with the appear-
ance of tau phosphorylated on multiple epitopes
recognised by the 12E8, AT8, tau-pT123 and tau-pT427
antibodies. The ability of TAOKs to phosphorylate tau
on pathogenic epitopes was investigated here using a re-
cently characterised TAOK inhibitor compound, which
inhibited tau phosphorylation in vitro and in HEK293
cells expressing exogenous TAOK2 and human tau. Cp
43 also decreased basal levels of tau-12E8 and tau-AT8
in differentiating rat neurons without inducing cytotox-
icity or causing significant changes in pre-synaptic pro-
tein expression levels in primary neurons.
The normal physiological functions of TAOKs in adult
brain remain to be determined but TAOK2 can regu-
late dendrite arborisation, spine maturation and axonal
outgrowth in the developing mouse brain [10, 49, 59, 65].
Here we have shown that endogenous TAOK activity and
tau-12E8 and tau-AT8 are increased as primary cortical
neurons undergo differentiation and that TAOK2, but not
TAOK1, is active catalytically when over-expressed in
transfected neurons. Furthermore, TAOK-pS181 immuno-
reactivity in lysates prepared from rat cortical neurons
was observed and this antibody recognised a protein band
that appeared to migrate with the same mobility as
TAOK2. These observations are consistent with a role
for TAOK2 in regulating neuronal maturation during
early murine brain development as reported previously
[10, 49, 59, 65]. TAOK expression and activity were also
detected in differentiating Tau35 primary neurons and in
FTLD-tau and control human iPSC-derived neurons.
However, only limited immunoreactivity with the TAOK-
pS181 antibody was observed in adult human asymptom-
atic brain sections when compared to AD and FTLD
brains, where strong TAOK-pS181 immunoreactivity oc-
curred at tangle structures. These results suggest that
Fig. 7 Cp 43 decreased tau phosphorylation in murine and human neuronal models of tauopathy. a Neurons were prepared from Tau35 transgenic
mouse embryos and incubated at 14 DIV with or without Cp 43 (10, 30 μM, 6 h) and lysates immunoblotted with antibodies to detect TAOK-pS181,
TAOK2, tau-pS262/S356 (12E8), tau-pS202/T205/S208 (AT8), total tau, BIII Tubulin or HA. b Quantitative analysis of the relative levels of phosphorylated
tau (12E8 and AT8) in Tau-35 primary neurons. The data are normalised to total tau and the bars represent the average ratio ± SEM (n = 6). c CTR or
FTLD (10 + 16 MAPT mutation) iPSC derived neurons (60 DIV) were incubated with or without Cp 43 (10, 30 μM, 6 h) and lysates immunoblotted with
antibodies to detect TAOK-pS181, TAOK1, TAOK2, tau-pS262/S356 (12E8), total tau or BIII Tubulin. d Quantitative analysis of the relative
levels of phosphorylated tau (12E8) present in Cp 43 treated iPSC derived neurons. Data are normalised to total tau and are expressed as
mean percentages ± SEM of the controls (n= 6). *p< 0.05; **p< 0.01, one-way ANOVA followed by multiple comparison using the Holm-Sidak method
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appropriate levels of TAOK activity are required for neur-
onal maturation in the developing brain whereas increased
TAOK activity in the adult brain may result in pathogenic
effects.
In differentiating primary cortical neurons tau was not
phosphorylated on T427 unless these cells were trans-
fected with TAOK2. Tau was however phosphorylated
on T123 where immunoreactivity was located in the nu-
cleus of differentiating neurons and phosphorylation levels
on this epitope were not increased by over-expression of
TAOK2. Previous studies have demonstrated enriched ex-
pression of the 1N4R tau isoform in the neuronal nucleus
but not in the cytoplasm or neurites, where the 0N3R fetal
tau isoform is predominantly expressed at this stage of dif-
ferentiation [6, 35, 42]. The absence of mature tau isoform
expression in the cytoplasm and neurites in differentiating
neurons and the lack of TAOK2 expression in the nucleus,
may account for the inefficient phosphorylation of tau on
T123 by TAOK2 observed here.
Tau phosphorylation and TAOK activity were also ex-
amined in an additional tauopathy. Immunohistochemical
analysis of FTLD-tau brain sections showed that active
TAOK-pS181, tau-pT123 and tau-pT427 each localised to
pre-NFTs and NFT structures. Primary cortical neurons
were also prepared from brains from Tau35 transgenic
mice, which overexpress a C-terminally truncated 35 kDa
htau fragment that is associated with tauopathies [4].
Treatment of these Tau35 mouse neurons with Cp 43
reduced tau phosphorylation on the 12E8 and AT8
epitopes. Human neurons were also produced using
iPSCs derived from control and individual with the
10 + 16 MAPT mutation which is associated with FTLD
and these differentiated cells expressed active TAOKs and
tau phosphorylated on S262/S356. Addition of Cp 43 de-
creased tau phosphorylation on the 12E8 epitope in these
FTLD iPSC derived neurons but we were unable to detect
tau-pT123 or tau-pT427. A previous study has shown that
these FTLD neurons express the foetal 0N3R tau isoform
at this time point (60 DIV) and it is possible that adult tau
isoform expression and enhanced TAOK activity are re-
quired for tau phosphorylation on T123 and T427 [53]. In
contrast, T123 and T427 were phosphorylated under
pathogenic conditions in FTLD-tau brain sections, where
all six tau isoforms are expressed, and tau-pT123 and tau-
pT427 localised to pre-tangles and tangles, where TAOK
activity occurred.
A number of kinases can phosphorylate tau in vitro
and to date GSK-3, MARK, JNK, p38, AMPK, Nuak1
and TAOKs have been shown to be active catalytically at
tangles in AD brain tissues [15, 21, 31, 57, 60, 67].
TAOKs can stimulate the catalytic activity of several of
these tangle-associated kinases, including MARK, JNK
and p38, and TAOKs could potentially phosphorylate
tau on additional pathological sites via such pathways
[25, 44, 56]. Indeed, TAOKs can phosphorylate and
activate MARK directly and both of these kinases can
phosphorylate tau on the 12E8 epitope [3, 56]. The ap-
pearance of TAOK activity at pre-tangle and tangle
structures during early AD (Braak stage II) and their
phosphorylation of tau on multiple residues, including
pathogenic sites such as T123 and T427, are consistent
with potential roles for TAOKs during early disease de-
velopment. Therefore, inhibitors of TAOK activity may
reduce aberrant tau phosphorylation and tau pathology.
In a previous study using breast cancer cell models, we
have shown that abnormal TAOK activity can contribute
to clustering of supernumerary-amplified centrosomes in
malignant cells and prevents multipolar mitoses and as-
sociated cell death [29]. Cp 43 can stimulate centrosome
declustering, multipolarity and mitotic catastrophe in
these centrosome amplified cancer cells selectively,
whereas normal bipolar cells continue to divide and
proliferate in the presence of this compound [29].
Aberrant TAOK activity can therefore induce cluster-
ing of supernumerary-amplified centrosomes in malig-
nant breast cells as well as stimulating pathological
tau phosphorylation in neurons and tauopathies and
TAOKs may therefore offer suitable therapeutic targets
for both diseases. To date, TAOKs are not reported to be
involved in any other diseases.
Tau kinase inhibitors have been used already to treat
tau transgenic mice, in order to slow or prevent the de-
velopment of tau pathology in these animals [28, 32, 46].
Previous studies have shown that inhibiting GSK3 re-
duces tau phosphorylation and ameliorates memory defi-
cits in transgenic mouse models of AD [7, 46, 47, 51].
Initial studies targeting GSK-3 produced encouraging re-
sults in pre-clinical studies but failed during clinical tri-
als due to off-target toxicity and the requirement for
GSK-3 activity to sustain normal cell function [39]. The
appearance of TAOK activity at NFTs in AD and FTLD,
and their phosphorylation of tau on multiple patho-
logical sites, suggests that these proteins could offer
novel and suitable alternative drug targets for the treat-
ment of neurodegenerative disorders.
Conclusions
In summary, we have shown that TAOKs are active and
co-localise with tangle structures in AD and FTLD brain.
We have used a new TAOK inhibitor to reduce tau
phosphorylation on sites associated with neurodegenera-
tion in human tauopathies and examined two new phos-
phorylation sites on tau (T123 and T427) that are
targeted by TAOKs and detected in AD and FTLD brain.
TAOK activity and tau phosphorylation on pathological
sites are also shown to be decreased by Cp 43 in vitro
and in neuronal and disease cell models. Our results
suggest compounds that inhibit the activity of these
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kinases could reduce tau pathology and potentially delay
associated cognitive decline with such effects providing
significant benefits for individuals with early symptoms
of dementia.
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Additional file 1: Table S1. Characteristics of the subjects whose brain
tissues were used in this study. PMD refers to post-mortem delay in hours
before samples were processed. (DOCX 16 kb)
Additional file 2: Figure S1. Cp 43 decreased tau phosphorylation in
rat primary cortical neurons. A. Quantitative analysis of cleaved active
Caspase 3 positive neurons (7 DIV or 17 DIV) treated with or without
30 μM Cp 43 (72 h). > 800 neurons were counted for each experimental
condition and bars represent mean percentages ± SEM (n = 4). B. Neurons
(14 DIV) were incubated without or with Cp 43 (5, 10 or 30 μM, 72 h) and
lysates immunoblotted with antibodies to detect Synapsin 1, Synaptophysin
or BIII tubulin. C. Quantitative analysis of the effects of Cp 43 on synaptic
protein expression levels normalised to BIII tubulin. Bars represent the
average ratio ± SEM (n = 7). D. Neurons (7 DIV) were treated with or without
Cp 43 for 6 h as indicated and lysates immunoblotted with antibodies
to detect tau-pS262/S356 (12E8), tau-pS202/T205/S208 (AT8), total tau or
BIII Tubulin. E. Quantitative analysis of the effects of increasing Cp 43
concentration on the levels of phosphorylated tau (12E8 and AT8
epitopes). Data are normalised to total tau and are expressed as
mean percentages ± SEM of the controls (n = 5). ** p < 0.01 *p < 0.05,
one-way ANOVA followed by multiple comparison with the Holm-Sidak
method. F. 7 and 17 DIV neurons were incubated with or without Cp 43
(1–30 μM) for 6 h. Bars represent the average ratio of the percentages of
LDH released versus total LDH ± SEM (n = 24; collected in 3 independent
experiments). Representative immunoblots and images are shown. Scale
bar = 10 μm. (TIF 815 kb)
Additional file 3: Figure S2. Blocking phospho-peptides abolished
epitope recognition by TAOK-pS181, tau-pT123 and tau-p427 antibodies.
A. Entorhinal cortex sections from AD (Braak VI) brains were immunostained
with antibodies to detect TAOK-pS181, tau-pT123 or tau-pT427 in the
presence (left side) or absence (right side) of their appropriate blocking
phospho-peptide epitopes (1 μM). B. In vitro kinase assays were carried
out using GST-TAOK1 (1–314) or GST-TAOK2 (1–314) and recombinant
htau (2N4R), and samples immunoblotted with tau-pT123 or tau-pT427
antibodies in the presence (right side) or absence (left side) of their
appropriate blocking phospho-peptide. Representative images and immuno-
blots are shown. Scale bar = 20 μm. (TIF 7890 kb)
Additional file 4: Figure S3. Tau phosphorylated on T123 was present in
the nuclei of rat primary neurons. A Neurons (7 DIV) were transfected with
IRES-GFP, TAOK2-IRES-GFP or TAOK2 K57A-IRES-GFP, fixed and immunostained
with antibodies to detect tau-pT123 (red) and Myc (magenta). Nuclei were
counterstained with DAPI (blue). Representative images are shown. Scale
bar = 10 μm. (TIF 409 kb)
Additional file 5 Figure S4 FTLD and control iPSC-derived neurons
expressed phosphorylated tau. A-D. FTLD (10 + 16 MAPT mutation) and
control iPSC-derived neurons (60 DIV) were fixed and immmunostained
with antibodies to detect total tau (red, A-B), tau-12E8 (green, A-B), tau-1
(green, C-D) and Map2 (red, C-D). Nuclei were counterstained with DAPI
(blue). Representative images are shown. Scale bar = 10 μm. (TIF 4365 kb)
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